Appeal No. 95-4791
Application 08/034,849
specification states (Spec., p. 2, l. 5-13):
DE-OS 32 13 389, United States Patent No. 4,507,285
and United States Patent No. 4,296,103, describe
chemically-stabilized chlorite matrices which are
suitable for an external or oral therapeutic use.
Besides various bacterial infections, the external
treatment of virus infections, such as herpes simplex
and herpes zoster, is deemed possible in this manner but
an intravenous administration for the treatment of HIV
infections is not possible.
B. Kuhne I and Kuhne II5
Canadian Patent 1,268,714 (Canada) describes “the use of
a composition consisting of an aqueous solution of a
chemically stabilized chlorite matrix for intravenous and
topical administration in tumor treatments” (Canada, p. 1, l.
13-16). Isotonic solutions of stabilized chlorite matrices
in cosmetics, for the sterilization of food and
drinking water, and as feed additives. General
areas of medical application are to be found in
the fields of disinfectants and chemoprophylaxis.
The stabilized activated oxygen according to the
invention can especially be used, for example, for
the treatment of skin diseases such as herpes simples
[sic], herpes zoster, acne or burns, or wound healing
disorders or for macrophage and phagocyte stimulation.
In particular, an arteriopathy and an alopecia areata
can be influenced significantly. With melanomes [sic]
significant remissions have been obtained.
5 We consider Canadian Patent 1,268,714 to be an
English translation of EP-200,156 and Australia 599,027 to be
an English translation of EP-200,157. We cite the English
publications.
6
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007